FEP Medical Policy Manual

FEP 1.03.05 Patient-Controlled End of Range Motion Stretching Devices

Effective Policy Date: July 1, 2019

Original Policy Date: March 2015

Related Policies:
None

Patient-Controlled End of Range Motion Stretching Devices

Description
Patient-controlled stretching devices are used at home to increase range of motion (ROM) in patients who have impaired functional status due to decreased ROM. We address two types of commercially available devices. Static progressive stretch (SPS) devices (eg, JAS, Static-Pro) provide low- to moderate-intensity stretching with a crank or ratchet that progressively increases the stretch within each session, and serial stretch devices (eg, ERMI) use hydraulics to alternate between periods of higher intensity stretch and relaxation.

OBJECTIVE

The objective of this evidence review is to evaluate whether patient-controlled stretching devices (static or serial) improve health outcomes in patients with a decreased range of motion.

POLICY STATEMENT

Patient-controlled end range of motion stretching devices are considered investigational.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.
BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

FDA REGULATORY STATUS

The U.S. Food and Drug Administration has determined that devices classified as “Exerciser, Non-Measuring” are considered class I devices and exempt from 510(k) requirements. This classification does not require submission of clinical data on efficacy, only notification to the Food and Drug Administration prior to marketing. Food and Drug Administration product code: ION.

RATIONALE

Summary of Evidence

For individuals who have functional limitations in ROM who receive SPS devices and physical therapy, the evidence includes RCTs, a systematic review, and case series. The relevant outcomes include symptoms, change in disease status, functional outcomes, and QOL. Three RCTs have evaluated SPS devices but comparators in each differed (physical therapy, a dynamic splint, and a serial stretch device). One RCT reported significant improvements in Disabilities of the Arm Shoulder and Hand questionnaire scores and shoulder ROM compared with physical therapy alone at the end of four weeks of treatment, with significant improvements maintained at the two-year follow-up. A second RCT evaluating SPS in the elbow found similar improvements in most ROM outcomes compared with dynamic splinting, except better Disabilities of the Arm Shoulder and Hand scores in the SPS group at 6 months and better flexion contracture in the dynamic splinting group at 12 months. A third RCT, which compared SPS with serial stretch devices, found greater improvements in WOMAC and knee flexion scores with the serial stretch devices. A systematic review and meta-analysis of case reports and series found that similar clinical efficacy for increasing elbow ROM and flexion can be achieved using dynamic splints, SPS devices, and static braces. It is not known whether patient compliance is higher with SPS devices because results have indicated these devices improve ROM faster than comparators. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have functional limitations in ROM who receive serial stretch devices and physical therapy, the evidence includes an RCT and observational studies. The relevant outcomes include symptoms, change in disease status, functional outcomes, and QOL. The best evidence consists of serial stretching with ERM devices used to treat knee ROM. One small RCT and a larger retrospective comparative study have reported that high-intensity stretching with ERM devices improved ROM more than lower intensity stretching devices in patients who were post injury or surgery. Other available data consist of retrospective case series that have demonstrated improved ROM in patients whose ROM had plateaued with physical therapy. The clinical significance of gains in this surrogate outcome measure is unclear. Further high-quality comparative trials are needed to determine whether these patient-controlled devices improve functional outcomes better than alternative treatments and identify the patient populations that might benefit. The evidence is insufficient to determine the effects of the technology on health outcomes.

SUPPLEMENTAL INFORMATION

Practice Guidelines and Position Statements

No guidelines or statements were identified.

U.S. Preventive Services Task Force Recommendations

Not applicable.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.
Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

REFERENCES


The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.
POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 2015</td>
<td>New policy</td>
<td></td>
</tr>
<tr>
<td>December 2016</td>
<td>Replace policy</td>
<td>Policy updated with literature review through June 13, 2016; references 7-9 and 11-12 added. Policy title changed to &quot;Patient-Controlled End Range of Motion Stretching Devices&quot;.</td>
</tr>
<tr>
<td>March 2018</td>
<td>Replace policy</td>
<td>Policy updated with literature review through January 8, 2018; no references added. Policy statement unchanged.</td>
</tr>
<tr>
<td>June 2019</td>
<td>Replace policy</td>
<td>Policy updated with literature review through January 9, 2019; no references added. Policy statement unchanged.</td>
</tr>
</tbody>
</table>

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.